Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE-LECIG intestinal levodopa + entacapone therapy in Parkinson's disease
2025-521048-39-00Phase 3Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of carbidopa/levodopa/entacapone in Parkinson's disease (PD) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Primary hyperdopaminergic symptom improvement. Planned start Aug 2025; status: authorised.
02
Drugs
carbidopa/levodopa/entacapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-521048-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521048-39-00.